Cognitive effects were improved and the expression levels of Aβ peptides were reduced as a result of the administration of antihuman APP therapeutic antibody Fab fragments (NAB61) in transgenic murine AD models [78]. The gene discussed is APP; the disease is Alzheimer disease.